The FDA classified a recall of 39,060 bottles of Clear Eyes Maximum Itchy Eye Relief as a Class II event after the manufacturer identified sterility concerns and potential contamination affecting a single lot.

New consensus guidance favors once-daily oral iron and simplified IV administration, including fewer test doses, premedications, and infusion visits. Several recommendations depart from established protocols and require formulation-specific clinical judgment.

HRSA’s revised 340B rebate pilot could require covered entities to purchase selected high-cost drugs at full price and recover discounts through manufacturer rebates beginning in 2027, prompting hospitals to evaluate data infrastructure, vendor readiness, and reimbursement workflows while legal and congressional challenges continue.

A multisociety consensus paper outlines hospital-level strategies to improve sepsis outcomes, emphasizing diagnostic stewardship, antimicrobial optimization, surveillance, infection prevention, and multidisciplinary infrastructure while prioritizing interventions judged most feasible and impactful for broad implementation.

An editorial in Obesity highlights emerging evidence that GLP-1 receptor agonists may provide benefits beyond weight loss and glycemic control, while emphasizing unresolved questions regarding muscle preservation, nutritional status, and potential effects on substance use disorders.

Atorvastatin reduced major cardiovascular events among adults aged 70 years and older without known cardiovascular disease, diabetes, or dementia, but the benefit did not translate into a statistically significant improvement in disability-free survival over nearly six years of follow-up.